Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies

NCT00256191 is registered in ClinicalTrials.gov with Cortice Biosciences, Inc. as lead sponsor.

NCT NCT00256191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00256191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies
Lead sponsor
Cortice Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2005
Completion date
February 28, 2007
Enrollment
45
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's disease, neoplasms, non-hodgkin's lymphoma